12–15% of all tumors lack immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [1] and are therefore termed triple-negative breast cancers (TNBC). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.